Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Lecozotan SR, lecozotan SR (SRA-333)
Lecozotan · 6 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | EXPERIMENTAL | - |
| C | EXPERIMENTAL | - |
| D | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| lecozotan SR (SRA-333) | DRUG | one of 3 doses of lecozotan sr dose for 6 months as an extension to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr |
| lecozotan SR | DRUG | evaluation of long term therapy with 3 doses of lecozotan sr ( 2, 5, and 10 mg)administered to patients with AD who have completed week 12 evaluations in the short-term study. Patient duration is 42 weeks. Arms include lecozotan sr 2 mg, 5mg, and 10 mg as well as donepezil. |
| Donepezil | DRUG | 10 mg donepezil QD dosed up to 40 weeks |
| Lecozotan | DRUG | - |
| Moxifloxacin | DRUG | - |
Inclusion Criteria: * Diagnosis of probable Alzheimer's disease * Current use of cholinesterase inhibitor * Able to give signed and dated informed consent and lives with appropriate caregiver at home or in community dwelling with caregiver accompanying patient to all visits and visiting patient at ...
Top 20 of 30 competitors
Lecozotan is an investigational small molecule being studied for the treatment of Alzheimer Disease. It has been evaluated in Phase 2 clinical development. Lecozotan is not approved for any indication and remains an experimental therapy under study.
Lecozotan targets HTR1A, the serotonin 1A receptor, and acts as an antagonist at this receptor. By blocking HTR1A, the drug is designed to modulate serotonergic signaling, a mechanism explored in Alzheimer Disease research. Lecozotan is a small molecule developed for neurological indications.
Lecozotan is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer has sponsored the clinical trial program for Lecozotan, including pharmacokinetic, cardiac safety, and formulation studies conducted in healthy volunteers and patients with Alzheimer Disease.
Lecozotan is in Phase 2 clinical development for Alzheimer Disease. It is an investigational drug and has not been approved by the FDA. All six of its registered trials are completed, and no trials are currently active.
Lecozotan has been studied in six completed clinical trials, including NCT00563732, a Phase 1 drug interaction study with digoxin; NCT00499642, a Phase 1 QTc interval study; NCT00494962, a Phase 1 tablet comparison study; and NCT00366483, a Phase 1 safety study in healthy young and elderly subjects.
Yes. Lecozotan SR and lecozotan SR (SRA-333) are alternative names for Lecozotan. The SR designation refers to a sustained-release formulation of the drug. All names refer to the same investigational compound developed by Pfizer for Alzheimer Disease.